NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
NeuroSense報告了其PARADIGM 2b期研究中PrimeC在ALS患者中的12個月分析結果；疾病進展較安慰劑緩慢了36%。
NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
NeuroSense報告了其PARADIGM 2b期研究中PrimeC在ALS患者中的12個月分析結果；疾病進展較安慰劑緩慢了36%。